Dynavax Technologies Corporation (DVAX) Announces Resignation Of Dino Dina From Board Of Directors

BERKELEY, CA--(Marketwired - October 07, 2014) - Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Dino Dina, M.D, has resigned from the Board of Directors. Dr. Dina was a director of the Company since 1997 and was the Company's Chief Executive Officer between 1998 and 2013.

"We are grateful for Dino's leadership and the contributions he made to Dynavax's development as a fellow Board member and during his 15-year tenure as our CEO," said Arnold Oronsky, Ph.D., Chairman of Dynavax.

Dr. Dina added, "With the recent completion of enrollment in the Phase 3 HEPLISAV-B™ clinical trial, Dynavax has achieved yet another milestone on the path to success for the company and the people who may benefit from its products."

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.